Drugmakers including Eli Lilly, AstraZeneca and AbbVie gained about 4% while rate-sensitive and AI-linked stocks fell, and the Russell 2000 traded more than 10% below its August record. Decliners outnumbered advancers by more than 4 to 1 on the New York Stock Exchange.
The stock market's losses on Wednesday were not spread evenly. They were sorted.
By about 1:45 p.m. Eastern, the S&P 500 was down about 1.3% at 7,707 and the Nasdaq Composite about 1.9%. The Dow Jones Industrial Average fell about 0.5%. The Russell 2000 index of smaller companies, down about 1% in the first hour of trading, had extended its loss to about 2.1%, leaving it more than 10% below its Aug. 14 record close of 3,068.42, the common definition of a correction. At about 2,725 it was roughly 11% below that peak. It has not yet closed there; Tuesday's close was about 9.3% below the record.
That is a gap of about 1.6 percentage points between the Dow and small caps, and it lined up with what each index holds.
Where the money went
The S&P 500's health care sector index rose about 2.2% in early-afternoon trading, the best performance among the 11 sectors. Eli Lilly, AstraZeneca and AbbVie each gained about 4%, and Amgen about 3.5%. Consumer staples were up about 1.7% at midday. Gains in UnitedHealth and Amgen, both Dow components, helped keep that index close to flat.
At the other end, the information technology sector index fell about 2.7% and consumer discretionary about 1.6%. The Nasdaq, heavy in technology, took the brunt.
Breadth was weak. Around midday, declining stocks outnumbered advancers by 4.42 to 1 on the NYSE and 3.78 to 1 on the Nasdaq, where 434 stocks hit 52-week lows and 19 reached new highs. The Cboe Volatility Index rose about 11% to near 17.
The setup
The selloff followed a period of unusual calm. Goldman Sachs analysts noted before the open that options prices implied historically small daily moves, which they said signified "how low conviction is in either direction." Money had also been pouring in: EPFR data, which begin in 2000, show no longer run of monthly inflows into U.S. equity funds than the 13 straight months recorded through September.
The hotter inflation report coincided with the selling, and it bears most directly on stocks sensitive to rates. Small companies tend to carry more floating-rate debt, so higher expectations for Fed increases weigh on them directly. Technology and AI-linked shares, priced on earnings far in the future, lose value when the rate used to discount those earnings rises. It was not the only catalyst: Bank of America fell after a regulatory charge and an earnings miss, AI infrastructure stocks extended a slide tied partly to borrowing costs, and Barclays downgraded two of the year's best-performing hardware stocks.
Health care and staples sit at the other end. Their earnings depend less on the economic cycle or on borrowing.
Market implications
Read generously, the day was a rotation rather than a retreat: investors stayed in stocks but moved into defensive sectors, which is why the Dow fell only about half a percent and why a 1.3% drop in the S&P 500 came alongside a 2% gain in health care.
Read cautiously, the calm has broken. Breadth this weak, a small-cap index trading in correction territory and a jump in volatility suggest more than sector rebalancing, especially after months of steady inflows left many investors positioned for further gains.
What to watch
Whether the Russell 2000 closes more than 10% below its record, Thursday's retail sales and producer prices, and whether health care holds its gains once the rate-driven selling eases.